We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Vir Biotechnology Inc
38 own
12 watching
Current Price
$0
$0.08
(0.3%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
3,466.13M
52-Week High
31.78
52-Week Low
18.05
Average Volume
0.01M
Dividend Yield
--
P/E Ratio
--
Market Capitalization3,466.13M52-Week High31.7852-Week Low18.05Average Volume0.01MDividend Yield--P/E Ratio--What does the Vir Biotechnology Inc do?
Vir Biotechnology Inc is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and cause hundreds of billions of dollars of economic burden each year. Current development pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. VIR-2218, an HBV-targeting siRNA, is in an ongoing Phase 1/2 clinical trial and initial data have demonstrated substantial reduction of hepatitis B virus surface antigen, or HBsAg. Based on initial data, VIR-2218 has been generally well-tolerated.
Read More
How much money does Vir Biotechnology Inc make?
News & Events about Vir Biotechnology Inc.
Ticker Report
1month ago
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) has been given a consensus rating of Moderate Buy by the eight analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating...
Zolmax
2 months ago
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) has been assigned an average recommendation of Moderate Buy from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy ...
Zolmax
2 months ago
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) CTO Ann M. Hanly sold 2,627 shares of the firms stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $22.77, for a total transaction of $59,816.79. Following the transaction, the chief technology ...
PR Newswire
2 months ago
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results PR Newswire DURHAM, N.C. and BEIJING, March 24, 2023 Company maintains priority focus on clinical programs to develop a...
Globe Newswire
3 months ago
Final draft guidance based on cost effectiveness evaluation of sotrovimabSAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UKs National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending ...
Frequently Asked Questions
Frequently Asked Questions
What is Vir Biotechnology Inc share price today?
Can Indians buy Vir Biotechnology Inc shares?
How can I buy Vir Biotechnology Inc shares from India?
Can Fractional shares of Vir Biotechnology Inc be purchased?
What are the documents required to start investing in Vir Biotechnology Inc stocks?
What is today’s traded volume of Vir Biotechnology Inc?
What is today’s market capitalisation of Vir Biotechnology Inc?
What is the 52-Week High and Low Range of Vir Biotechnology Inc?
What percentage is Vir Biotechnology Inc down from its 52-Week High?
What percentage is Vir Biotechnology Inc up from its 52-Week Low?
Current Price
$0
$0.08
(0.3%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.